AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
The Janssen-Cilag atypical once-daily antipsychotic paliperidone (Invega) has been granted market authorisationin Europe.
The company reported that in studies paliperidone prolonged-release tablets significantly reduced schizophrenia symptoms as early as the fourth day after treatment was initiated. Patient functioning also improved.
The studies also showed paliperidone prolonged-release tablets to be generally safe and well tolerated with extrapyramidal side effects and weight gain comparable to placebo at the recommended dose of 6mg.
A longer-term study…